Narrow search
Showing 1 - 10 of 18
Cover Image
The Effect of FDA Advisories on Branded Pharmaceutical Firms' Valuations and Promotion Efforts
Conti, Rena M.; Huskamp, Haiden A.; Berndt, Ernst R. - National Bureau of Economic Research (NBER) - 2011
The US Food and Drug Administration (FDA) expends considerable efforts in regulating medications approved for use. Yet the impact of medication labeling changes on brand pharmaceutical products, and whether and what firms do to respond to increased information regarding the safety and efficacy...
Persistent link: https://www.econbiz.de/10009325511
Cover Image
Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century After the 1984 Waxman-Hatch Legislation
Berndt, Ernst R.; Aitken, Murray L. - National Bureau of Economic Research (NBER) - 2010
following initial generic entry and by 24 months to 65, in 2009 the comparable generic price indexes are 68 and 27, respectively … patent has expired. Across all nine therapeutic areas, at 24 months post-generic entry, the weighted mean reduction in …
Persistent link: https://www.econbiz.de/10008682661
Cover Image
Pricing and Reimbursement in U.S. Pharmaceutical Markets
Berndt, Ernst R.; Newhouse, Joseph P. - Kennedy School of Government, Harvard University - 2010
comment on very recent developments concerning the entry of large retailers such as Wal-Mart into domains traditionally …
Persistent link: https://www.econbiz.de/10010627802
Cover Image
Specialty drug prices and utilization after loss of U.S. patent exclusivity, 2001-2007
Conti, Rena M.; Berndt, Ernst R. - National Bureau of Economic Research (NBER) - 2014
estimated prices of these drug undergoing LOE fall with generic entry. Second, we estimate reduced form random effects models of … utilization subsequent to LOE. We observe substantial price erosion after generic entry; average monthly price declines appear to … entry, but this result appears to be largely driven by oral drugs. We discuss second-best welfare consequences of these …
Persistent link: https://www.econbiz.de/10010950850
Cover Image
Pricing and Reimbursement in U.S. Pharmaceutical Markets
Berndt, Ernst R.; Newhouse, Joseph P. - National Bureau of Economic Research (NBER) - 2010
comment on very recent developments concerning the entry of large retailers such as Wal-Mart into domains traditionally …
Persistent link: https://www.econbiz.de/10008531891
Cover Image
Pricing and Reimbursement in U.S. Pharmaceutical Markets
Berndt, Ernst R.; Newhouse, Joseph P. - 2010
comment on very recent developments concerning the entry of large retailers such as Wal-Mart into domains traditionally …
Persistent link: https://www.econbiz.de/10014191301
Cover Image
Auditing the Prescription Drug Consumer Price Index in a Changing Marketplace
Frank, Richard G.; Hicks, Andrew; Berndt, Ernst R. - National Bureau of Economic Research - 2022
The Bureau of Labor Statistics' Prescription Drug Consumer Price Index (CPI-Rx) has been the focus of considerable controversy in recent years. The CPI-Rx limits its sampling frame to transactions in retail outpatient outlets, and excludes prescription pharmaceuticals dispensed in hospitals,...
Persistent link: https://www.econbiz.de/10013388804
Cover Image
Pricing in the Market for Anticancer Drugs
Howard, David H.; Bach, Peter B.; Berndt, Ernst R.; … - In: Journal of Economic Perspectives 29 (2015) 1, pp. 139-62
In 2011, Bristol-Myers Squibb set the price of its newly approved melanoma drug ipilimumab—brand name Yervoy—at $120,000 for a course of therapy. The drug was associated with an incremental increase in life expectancy of four months. Drugs like ipilimumab have fueled the perception that the...
Persistent link: https://www.econbiz.de/10011156823
Cover Image
Costs, Institutional Mobility Barriers, and Market Structure: Advertising Agencies as Multiproduct Firms
Silk, Alvin J.; Berndt, Ernst R. - National Bureau of Economic Research (NBER) - 1994
low fixed costs and minimal entry barriers, both media-specific scale and scope economies are available and can be …
Persistent link: https://www.econbiz.de/10005248932
Cover Image
Advanced purchase commitments for a malaria vaccine: estimating costs and effectiveness
Berndt, Ernst R.; Glennerster, Rachel; Kremer, Michael R.; … - London School of Economics (LSE) - 2005
To overcome the problem of insufficient research and development (R&D) on vaccines for diseases concentrated in low-income countries, sponsors could commit to purchase viable vaccines if and when they are developed. One or more sponsors would commit to a minimum price that would be paid per...
Persistent link: https://www.econbiz.de/10011071268